058820 — CMG Pharmaceutical Co Income Statement
0.000.00%
- KR₩297bn
- KR₩273bn
- KR₩94bn
- 50
- 22
- 16
- 15
Annual income statement for CMG Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 58,623 | 64,460 | 69,475 | 82,197 | 93,907 |
Cost of Revenue | |||||
Gross Profit | 28,923 | 31,210 | 33,451 | 40,901 | 43,703 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 56,110 | 63,906 | 66,275 | 79,545 | 86,804 |
Operating Profit | 2,513 | 554 | 3,200 | 2,652 | 7,103 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 3,837 | 569 | 3,549 | -1,255 | 6,731 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3,051 | 215 | 3,165 | -388 | 6,455 |
Net Income Before Extraordinary Items | |||||
Net Income | 3,051 | 215 | 3,165 | -388 | 6,455 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 3,051 | 215 | 3,165 | -388 | 6,983 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 25.7 | 7.48 | 12.9 | -1.15 | 21.4 |
Dividends per Share |